We’re proud to celebrate #Juneteenth, a powerful reminder of the resilience, strength, and enduring spirit of the African American community. #FreedomDay

Today we join ALS/MND Alliance in celebrating a global day of recognition and awareness for ALS/MND disease. At Athira, we're advancing our investigational ALS treatment, ATH-1105, for the potential benefit of the ALS community. bit.ly/4aITwgv #ALSMNDWithoutBorders

Thank you all who joined our webinar on the LIFT-AD clinical trial and endpoints this past week! Missed the session and interested in learning more about the trial and need for effective #Alzheimers treatments? Check out the webinar recording here: bit.ly/3zrFW3O $ATHA

This Alzheimer’s and Brain Awareness Month, we’re honored join the conversations bringing awareness, understanding and support for the #Alzheimers community. Hear more from our CMO Javier San Martin, M.D. on the unmet need for new, effective therapies for patients. #ENDALZ

Pride creates a space of reflection, solidarity, empowerment and joy. As we wrap up #Pride month, join us in recognizing the impact of pride in fostering an inclusive and supportive environment promoting diversity, equity, and support, which we aim to nurture at Athira.

As scientific pioneers, we’re taking a new approach to tackling Alzheimer's disease. Listen to CEO Mark Litton, Ph.D. explain fosgonimeton’s mechanism of action in a recent conversation with Precision AQ:

The last patient has completed dosing in our Phase 2/3 LIFT-AD clinical trial evaluating #fosgonimeton in mild-to-moderate #Alzheimers disease, with topline results anticipated by end of Q3 2024. Read the full announcement: investors.athira.com/news-releases/… $ATHA

What’s at stake for us? Developing therapies to counteract progression of neurodegenerative disease. President & CEO Mark Litton, Ph.D. joined Life Science Leader’s Wayne Koberstein to highlight our approach, progress, and future. bit.ly/4cO95W4 #CompaniesToWatch

Disease-modifying treatments are pivotal to effectively tackle #Alzheimers and potentially reverse neurodegeneration progression. Hear from Dr. Porsteinsson on the need for new treatments to reduce patient burden below. Listen to the full webinar: bit.ly/3zrFW3O

Last week, the #AthiraTeam gathered for an ice cream social hour at our Seattle office to catch up and decompress over tasty treats. Big thank you to our admin team for hosting the event, we’re grateful for the opportunity to bring the team together!

We participated in the 2024 Alzheimer's Association International Conference (AAIC), where our team presented preclinical data demonstrating new insights into the mechanism by which #fosgonimeton protects neurons from Alzheimer’s disease-related pathology. investors.athira.com/news-releases/… #AAIC24

Today we reported our second quarter 2024 financial results and provided recent pipeline and business updates. See full details here: investors.athira.com/news-releases/… $ATHA

That’s a wrap on #AAIC24! Thank you for joining our discussion of #fosgonimeton’s neuroprotective preclinical activity in #AD models. See you next year!

The #Alzheimers space is poised for significant developments in the second half of 2024. In her recent BioSpace article, Heather McKenzie summarizes key data readouts, including our LIFT-AD Phase 2/3 topline results of #fosgonimeton as a potential #AD treatment. bit.ly/3LNtmPw

Fosgonimeton has the potential to address the mild-to-moderate stage of #AD by providing neuroprotection and neuronal restoration. Stay tuned as we report topline data from our Phase 2/3 LIFT-AD clinical trial in Alzheimer's. Learn more: bit.ly/48NcRwO #ENDALZ

Our Phase 2/3 LIFT-AD Study is evaluating the safety and efficacy of #fosgonimeton for the treatment of mild-to-moderate #AlzheimersDisease. Hear more on our company progress from CEO Mark Litton, Ph.D. as we approach our topline data readout of the clinical trial.

#ICYMI – Take a deep dive into our latest corporate and pipeline updates, company highlights, news, and events compiled for easy access. See it here: bit.ly/4frZxlh

Today we announced the topline results from our Phase 2/3 LIFT-AD Study of #fosgonimeton for mild-to-moderate Alzheimer’s disease. Read the full release and join our live webcast today at 4:30 pm ET, where management will discuss the study results: bit.ly/3XsdVmy

Athira Pharma will focus on advancing the clinical development program for ATH-1105 as a potential treatment for neurodegenerative diseases, including amyotrophic lateral sclerosis (#ALS) and Alzheimer’s Disease (#AD). Read the full announcement: bit.ly/3ZsXN5v